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Measuring Costs and Quality of Life for Venous Leg Ulcers 
 
Introduction 
 
There is a lack of nationally representative and recent data on the prevalence of venous leg ulcers 
(VLUs) in the Australian setting. In a 1991 study set in Perth, Western Australia, prevalence was 
estimated at 0.62 per 1000 in the general, metropolitan population (1). Prevalence of VLUs was 
highest in older age groups with a prevalence of  3.3 per 1000 in adults 60 years and older (1). As 
the ageing population in Australia is increasing (2), it follows that the prevalence and incidence 
of VLU has likely increased over time. Thus, prevalence estimates from the 1990’s likely 
underestimate current prevalence.  
 
Not only do VLUs represent a growing health burden, they also represent a condition which is 
expensive to treat for both patients and the health care system. Worldwide, studies have estimated 
annual costs of up to €2585, €1994  (cost of treating an initial ulcer, per patient, limited to health 
system perspective) and €9569 (direct and indirect costs, per patient, societal perspective) in 
Sweden, the UK and Germany respectively (3, 4). While these estimates illustrate the potential 
for high costs, due to differences in health care systems and services these costs may not reflect 
the situation in Australia. Out-of-pocket costs of consumables alone have been estimated at $27.5 
million per year for Australians over 60 years with VLUs, although this figure may be 
underestimated due to underlying data limitations (5).   
 
In Australia, the total, direct costs of treating VLUs (in public and private hospitals and 
residential care settings) was estimated to be US$802.55 million (±US$307.46 million) (6). This 
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estimate does not appear to include the costs in the non-residential care community setting, such 
as general practitioner visits, of treating VLU. This presents a significant gap in our knowledge 
of VLU costs.  
 
In addition to the economic burden, VLUs also impact negatively on social functioning and 
reduce quality of life (QoL) (7, 8). There is limited local data about the effect of VLU on QoL, 
though it is expected to be significant. Elsewhere, a review described the impact of VLU on QoL 
as “profound” (7). Iglesias et al. describe an EQ-5D score, measured on a scale between 0 (death) 
and 1 (perfect health), of 0.62 associated with VLU (9). Greater understanding of the impact of 
VLUs on QoL would help to inform economic models. 
 
Australian guidelines recommend compression therapy (CT) as the primary treatment for VLUs 
(10, 11); however, evidence suggests many people do not receive guideline-based care (1, 12). 
Coyer et al. (13) identify three main evidence-practice gaps, relating to knowledge, costs and 
systems, whereby care pathways are inconsistent.  Yet, implementation of guideline-based, or 
optimal, care may represent improved health benefits and have important cost implications. For 
example, use of guidelines has been shown to reduce the costs of healing VLUs (14).  
 
No study in the Australian setting compares the resources used or time-to-healing of optimal 
(guideline-based) care and usual (standard) care scenarios for VLUs. However, we do know that  
care pathways which increase access to specialist wound clinics and CT improve healing 
outcomes of leg and foot ulcers in the Australian setting (15) and  evidence-based practice has 
demonstrated improved healing outcomes in other settings (14). Additionally, overall, we know 
little about the QoL benefits of optimal care as compared to usual care.  
 
The present study is part of a larger project. The overall project will perform an economic 
evaluation to capture the costs and benefits of providing optimal care to VLU patients. The 
project will bridge knowledge gaps regarding the implementation of guideline-based/optimal care 
and contribute important knowledge of the costs, QoL and healing outcomes associated with 
optimal care in the Queensland, Australia setting. The present study describes costs of care for 
VLU patients and the impact on QoL associated with VLUs. Given the increasing population size 
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affected by VLUs and the substantial economic burden and reduced QoL associated with VLUs, 
this research has significant implications for patients, health professionals and healthcare policy 
makers.  
 
Methods 
 
Participants and setting 
 
Recruitment occurred at four sites in Queensland, Australia: one private specialist wound clinic, 
one hospital outpatient clinic and two community care clinics.  
 
Patients attending the private specialist clinic and the community clinics were charged standard 
fees with no subsidy and those attending the outpatient clinic were bulk-billed (no out-of-pocket 
costs to patients). Patients attending the community care clinics pay an out-of-pocket fee for each 
appointment, and are charged separately for dressings used. The clinics arrange delivery of 
dressings to patients and these dressings are then brought to and used at subsequent 
appointments. Patients attending the clinics are seen by registered nurses, podiatrists, dietitians 
and occupational therapists. 
 
The public hospital outpatient clinic provides a bulk-billed service, with all dressings and 
consultancy fees covered with no out-of-pocket costs to the patient. Healthcare professionals in 
attendance include a vascular surgeon, registered nurses and occupational therapists. 
 
Patients attending the specialist wound clinic are charged a fee for each appointment which 
covers the cost of consultancy and all dressings. Patients are seen by a multidisciplinary team 
comprised of a vascular specialist, a wound nurse practitioner candidate, a podiatrist and a 
registered nurse. Patients receive tailored wound dressing plans, designed to be managed by the 
patient or primary carer outside the clinic, through further clinic visits, or augmented through 
telehealth. 
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Patients with a VLU who met the inclusion criteria were invited to participate. Participants were 
eligible if they were over 18 years of age, the principal diagnosis was VLU (or mixed/arterial 
with predominantly venous origin), and if they could provide informed consent. Exclusion 
criteria included leg ulcers not of venous origin, inability to comply with the protocol of the study 
and cognitive impairment. Recruitment occurred between December 2016 and September 2017. 
Data were collected at study admission (baseline) and at one month, three month and six month 
follow-ups. Participation or non-participation in the study did not impact upon the care received 
by patients.  
 
Data collection 
 
Information on patient demographic, medical history, comorbidities and ulcer characteristics 
were collected upon recruitment at baseline. Ulcer characteristics – including time of first onset, 
duration, number of wounds, current ulcer history and clinical assessment (size, ankle brachial 
pressure index (ABPI) if available, whether new or recurrent, time-to-healing, time to recurrence 
and exudate description) – were recorded. Body mass index (BMI) was calculated and 
categorised as per the World Health Organisation classification (16). Medical history and risk 
factors were sourced from patients and clinicians and were confirmed and supplemented by 
medical record review subject to availability.  Data on type of health services provided, 
investigations, types of dressings and bandages used, medication, travel, product and service 
patient out-of-pocket costs were recorded,. Data on QoL were collected using the EQ-5D-5L tool 
(17) at baseline and again at one, three and six months. Follow-up data were collected during 
clinic visits or through telephone interviews.   
 
Definitions  
 
For data analysis, patients were classified into two groups based on collected data: those 
receiving guideline-based prevention and treatment or “optimal care” and those receiving 
standard treatment or “usual care” at baseline. These classifications were made irrespective of the 
clinic of recruitment. Optimal care was defined as those patients who, during the study period and 
before healing, had at least one session of ankle brachial pressure index (ABPI) assessment to 
 
 
5 
 
confirm venous origin (0.8 ≤ ABPI ≤ 1.2), or toe pressure, or reason as to why ABPI was not 
performed and who received CT (compression bandages, compression hosiery or tubular 
compression bandage applied in three layers (18)). All other participants not meeting the criteria 
for optimal care were classified as receiving usual care. The treatment recorded at baseline was 
assumed to continue for the study duration or until healed. It was not possible to ascertain patient 
compliance with treatment unless noted in the medical records. Time-to-healing was defined as 
the number of months that each ulcer took to heal, from the time the patient was recruited into the 
study.   
 
 
Costs 
 
Data on costs of travel to receive wound care, consultancy with health professionals and products 
used allowed estimation of participants’ average weekly costs. Patient out-of-pocket costs 
included costs to patients for travel and parking, private clinic consultation fees and wound care 
products. Health system costs included the Medicare costs of medical services (doctors, 
specialists, nurses and allied health professionals) and investigations as well as prescription costs 
for medications listed on the Pharmaceutical Benefits Scheme. Thus, this study takes a societal 
perspective. Costs are reported in Australian dollars unless otherwise indicated. 
 
Travel and parking costs  
 
Participant’s travel and parking costs were estimated by capturing the mode of travel to the clinic, 
out-of-pocket costs and the frequency of attendance. Those who travelled by public transport, 
community transport or taxi provided exact travel costs. Car travel costs were calculated by 
multiplying the distance from clinic to participants’ homes in kilometres by $0.66 (19).  We 
assumed the same travel mode for each clinic visit. 
 
 
 
 
 
 
6 
 
Costs of medical services 
 
The health services cost items included were all consultations with a community-based nurse, 
podiatrist and other allied health professional and medical specialists. Health services were 
valued in line with the Australian Federal Government reimbursements via Medicare or the 
Medical Benefits Schedule (MBS). Nurse practitioner, vascular surgeon, podiatrist and 
occupational therapist costs were based on MBS items 82215, 104, 10962 and 10958 respectively 
(20). Enrolled, registered and student nurse time costs were calculated based on hourly salary 
(21),  assuming a 30 minute consultation in the absence of recorded appointment end time. The 
specialist wound clinic medical service was the patient out-of-pocket consultation fee which 
included the cost of consumables.   
 
Additional to their regular attendance at a clinic or through a home nursing service, many patients 
also used other healthcare services (e.g. GP visits). These costs were calculated as a product of 
the cost of the visit to the service used and the frequency of service access.  
 
Wound product costs 
 
Product use data were collected through medical chart review, consultation with clinicians or 
observation during clinic visits by research staff. Consumable item costs were based on a review 
of market prices and are available in a spreadsheet format from the authors on request. Product 
use recorded included: primary/secondary dressings (e.g. absorbent dressings), compression 
systems (e.g. short-stretch bandages/hosiery), topical medications (e.g. antimicrobial ointments), 
skin care items (e.g. barrier creams), cleansers and other disposables (e.g. tape).   
 
Quality of life 
 
The EQ-5D-5L (17) tool was used to capture QoL data. EQ-5D-5L is a generic, preference-based 
tool which measures QoL according to five dimensions: mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression (17). For each dimension, respondents were asked to 
choose from five levels to indicate whether they experienced any problems from each dimension 
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of health. EQ-5D-5L survey answers were valued and transformed to a utility score using a 
scoring algorithm developed from a UK general population sample (22).  
 
Statistical Analysis 
 
Baseline characteristics and wound clinical outcomes at different time points for patients 
receiving optimal care and usual care were compared using a combination of t-tests, Mann-
Whitney tests, z tests, Fisher’s exact tests and median tests, as appropriate. Data were analysed 
using IBM SPSS Statistics 23 and z tests were performed using an online calculator (23). A 
significance level of 0.05 was used in the interpreting of the statistical test results. Median and 
mean time-to-healing was calculated in order to ensure comparability to previous studies. 
 
Two patients had unknown costs related to travel and three patients had unknown costs related to 
product use. The multiple imputation procedure in SPSS was used to impute ten complete data 
sets to calculate the total cost estimate. Due to a small sample size, the Fisher’s exact test was 
deemed most appropriate to test for differences in numbers of ulcers healed at one, two, three and 
six months. 
 
Ethics 
 
This study was approved by the Metro South Health Service District Human Research Ethics 
Committee (HREC) and Queensland University of Technology (QUT) Human Research Ethics 
Committees (approval numbers HREC/16/QPAH/370 and 1600000934, respectively). Written 
informed consent was obtained from all participants. 
 
Results 
 
Participants’ baseline information is summarised in Tables 1-3. For all tables the available data 
were used, thus not all figures displayed included patients with missing data. Eighty-one 
participants were recruited; however, one patient had most baseline data missing and was also 
lost to follow-up by one month data collection, and thereby was excluded from analyses. Fifty-
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four patients were classified into the usual care group and 26 patients into the optimal care group. 
At three months, 22.5% of participants were lost to follow-up. 
 
The majority (68.6%) of participants were overweight or obese and were over 70 years of age 
(n=56, 70%) (Table 2). At baseline, the majority (81.3%) had venous insufficiency and reduced 
mobility (87.5%) recorded on their medical records (Table 2). Median ulcer duration at baseline 
was 10 months (IQR=42) for all patients (Table 3). By definition, all optimal care participants 
received CT. The majority (n=33, 61.1%) of usual care patients received CT as part of their care.  
 
 
 
 
➔ Insert Table 1 
➔ Insert Table 2 
➔ Insert Table 3 
 
Average weekly costs of managing ulcers in the community are presented in Table 4. Average 
weekly cost was estimated at $214.61 for those in the usual care group and $294.72 in the 
optimal care group. This result was significant (p=0.04). Total patient out-of-pocket costs per 
week were significantly higher for patients receiving optimal care (p=0.016). 
 
➔ Insert Table 4 
➔ Insert Table 5 
➔ Insert Table 6 
 
The average ulcer healing time in the usual care group (3.9 months) was longer compared to the 
optimal care group (2.7 months) (p = 0.045). While the medians of the two care groups were 
identical (3), the median test results rejected the null hypothesis that the medians in both groups 
were identical as there was a larger proportion of patients in the usual care group with time-to-
healing greater than the overall median compared with optimal care group (Table 6). 
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Service Provider  
 
➔ Insert Figure 1 
 
Most patients (85%) received care from a registered nurse (tabulated data not shown). Similar 
proportions of optimal and usual care participants accessed registered nurses for care (Figure 1). 
A larger proportion (37%) of usual care participants received care from a vascular surgeon 
compared to optimal care participants (19.2%) while a larger proportion of optimal care 
participants received care from enrolled nurses (11.5%) and podiatrists (23.1%) than did usual 
care (3.7% and 14.8% respectively) patients. Most participants (61.5% of optimal care and 53.7% 
of usual care participants) accessed two or more service providers at baseline. A larger proportion 
of usual care participants accessed three service providers at baseline, 20.4% compared to 7.7% 
of optimal care participants.  
 
Additional services use 
 
➔ Insert Figure 2 
 
At baseline 52 participants (n=18, (69.2%) optimal care, and n=34, (63%) usual care) used 
services additional to their main clinic attendance for ulcer wound care (Figure 2). 
 
Total wound management costs by clinic 
 
➔ Insert Figure 3 
 
The total weekly cost of care provision by the specialist wound clinic was $445.13, of which 
$123.00 were health system costs and $322.13 were patient out-of-pocket costs (Figure 3). The 
costs associated with primary consultations appears to be the main contributor to high overall 
costs of care at the specialist wound clinic. Total weekly costs of care by the community wound 
clinics were $214.36, comprising $108.52 in health system costs and $105.84 in patient out-of-
pocket costs. The cost of “other” medical services appear similar for all categories, perhaps 
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because the care is mostly from community services, and therefore invite fees of similar 
magnitude. Product costs fell almost exclusively onto patients attending the specialist wound 
clinic and the community clinics. Patients who attended the specialist wound clinic paid $105.34, 
while those attending community clinics paid $68.87. The hospital outpatient clinic incurred 
health system product costs of $58.00 with no out of pocket costs to patients (Figure 3). 
 
Discussion  
 
Costs 
 
We present detailed findings of the cost of treating VLUs in the community setting in Australia. 
To our knowledge this is the first study to present such detailed costs for this setting. 
Understanding costs is the first step to assessing cost-effectiveness and to understanding more 
fully the burden this chronic health condition poses. These results have significant implications 
for VLU patients, policy makers and health professionals.  
 
We estimated an average total weekly cost of $214.61 and $294.72 for those in usual and optimal 
care groups respectively. The optimal care group had higher costs overall, appearing to be driven 
by a higher cost of consultancy and product costs. Given the majority of patients in the optimal 
care group attended the specialist wound clinic, it is likely the out-of-pocket payment to the clinic 
influenced these results. However, the extra cost of attending the specialist wound clinic may be 
offset by factors such as faster time-to-healing. 
 
A 2010 study estimated out-of-pocket costs to patients of managing VLU, finding a cost of $114 
($157.6, 2018 dollars) per month (24, 25), while the present study estimated out-of-pocket costs 
of between $104.25 and $178.99 per week, which seems to be substantially different. One point 
of difference for the study was that participants self-reported travel and consultation costs, and as 
the authors suggest may have underestimated them for use of private vehicles (24), while in the 
present study costs of using a car for travel was calculated by the research team and consultation 
costs were collected prospectively by the research team.  
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A report (5) assessed cost-effectiveness of VLU treatment in the Australian context. However, 
the report was unable to include out-of-pocket costs to patients for travel to wound clinics in 
economic models due to inadequate data (5). This demonstrates the importance of the present 
study in addressing this gap.  
 
QoL 
 
The baseline utility score, 0.67 (SD±0.24), for all patients at baseline (i.e. in the unhealed ulcer 
state) was similar to that found by Iglesias et al. (9), who reported a score of 0.62 (standard error 
0.02) based on the EQ-5D tool. However, when comparing the type of care received, while usual 
care participants scores were similar to those reported by Iglesias et al. (9), optimal care patients 
had a 0.75 (SD±0.16) average utility score at baseline. As participants were not matched by 
characteristics, it is not necessarily surprising that the groups differed. After three months, the 
results of the present study were slightly higher than those reported by Iglesias et al. (9) for the 
same time point.  
 
Healing outcomes 
 
Previous work found a median time to ulcer healing of 12 weeks (3 months) (15) which compares 
similarly to our median findings of 3 months (IQR=3 for usual care; IQR=1.5 for optimal care) 
for both optimal and usual care groups. Time-to-healing was significantly different between usual 
care and optimal care groups. It is expected that decreased time-to-healing may reduce overall 
costs for treating VLU, despite the continued recommendation for CT which incurs additional 
costs. Apart from costs, considering the negative social functioning and QoL burden that ulcers 
can place on patients (7, 8), reduced time-to-healing may have implications for improved QoL 
and social function. 
 
The finding that 61.5% of optimal care patients and 53.7% of usual care participants accessed 
two or more service providers is consistent with the literature which suggests that patients often 
have to seek multiple pathways/providers to receive care (15).  
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We described a 61.1% rate of CT in the usual care group received for VLU care. With CT being a 
significant factor in guideline based care, this low rate is concerning, particularly as these patients 
continue to pay out-of-pocket costs for care, however are not receiving guideline-based 
treatment. A comparison could also be drawn between the lower costs of usual care, and the 
lower rates of CT usage - compression bandaging systems and hosiery significantly contribute to 
upfront costs, particularly with the lack of reimbursement in place for this therapy (26). 
 
Limitations 
 
The type of wound care (e.g. compression/no compression) provided was recorded at baseline, 
and was assumed to continue throughout the study. Recall bias may have influenced estimation 
of the costs for health-professional visits outside of the main treatment visit as this relied on 
patient self-reported data. We assumed that patients used the same transport mode for all visits as 
travel costs were calculated from baseline data.  
 
Participants were recruited into the study with an existing ulcer and may have been receiving 
treatment for this ulcer for several months prior to recruitment. Hence time-to-healing may have 
been underestimated.  
 
Participants were classified according to the available data. As such, some patients may have 
been misclassified, for example, they were receiving CT but ABPI data were unavailable and so 
were classified into usual care. Some patient follow-ups were conducted via telephone and relied 
upon self-reported data, without inspection of the wound by a healthcare professional.  
We did not compare the compression systems used or the level of compression used by 
participants. However, the Australian and New Zealand Clinical Practice Guideline for the 
Prevention and Management of Venous Leg Ulcers recommend that some compression is better 
than no compression, and further do not recommend use of a specific type of compression system 
but rather a range that is acceptable depending on a range of patient characteristics including 
patient tolerance (10).  Data were not collected on patient compliance with recommended 
therapy. Other studies have found that patient compliance with CT may be limited and this could 
be the subject of further enquiry (27).  
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Conclusion 
 
Patients receiving guideline-based optimal care incur higher costs initially, but these costs are 
expected to be outweighed by the long-term gains through fast healing times and improved 
quality of life. The higher costs of optimal care could be a contributing factor to the lower rates of 
patients receiving it, particularly as the majority of the costs are incurred by patients through 
product and service costs. If we are to begin closing the gap between the rates of optimal and 
usual care for patients, consideration should be given to providing reimbursement for wound-
related costs such as dressings, CT and healthcare provision.  
 
In addition, higher costs for optimal care could be outweighed by long-term savings through 
faster healing times, reduced recurrence and hospitalisation avoidance. This will be explored in 
an economic evaluation of optimal and usual care for VLU, using the data provided in this paper. 
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